Achiron A, Zoldan Y, Melamed E
Department of Neurology, Beilinson Medical Center, Petach-Tiqva, Israel.
Clin Neuropharmacol. 1990 Jun;13(3):248-52. doi: 10.1097/00002826-199006000-00008.
Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with sulpiride, a selective D2-receptor antagonist. We describe six patients who developed tardive dyskinesia after treatment with sulpiride for depression or gastrointestinal symptoms. In three patients, involuntary movements emerged during the course of treatment and in the others only after discontinuation of the drug. These cases indicate that sulpiride can cause tardive dyskinesia and that this drug should be administered with caution.
虽然迟发性运动障碍是传统抗精神病药物持续治疗已知的不良反应,但与选择性D2受体拮抗剂舒必利相关的报道却很少。我们描述了6例在使用舒必利治疗抑郁症或胃肠道症状后出现迟发性运动障碍的患者。3例患者在治疗过程中出现不自主运动,其他患者则在停药后才出现。这些病例表明舒必利可导致迟发性运动障碍,应谨慎使用该药。